Treace Medical Concepts Logo
US89455T1097
A3CM04
TMCI

Treace Medical Concepts

Chargement des cours...

Prévisions

L'objectif de cours moyen des analystes est de 5,92 € (-74,13 %). La médiane est de 5,92 € (-74,13 %).

Acheter
  3
Conserver
  5
Vendre
  1

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Treace Medical beats Q2 forecasts; shares jump about 24% premarket

    Treace Medical reported Q2 revenue of $45.4 million and an adjusted loss of $0.24 per share, with both revenue and EPS beating consensus estimates. The company cut operating expenses by 8% and reduced cash burn since the start of the year by 57%, lowering the net loss to $15.9 million. Treace slightly raised its full-year revenue guidance to $204–212 million and narrowed the adjusted EBITDA loss to $3–5 million, citing accelerated case volume and several product launches as drivers. The stock rose about 24% in premarket trading in response to the stronger results and the improved outlook. » Plus sur de.investing.com


  • Treace Medical Concepts reports Q4 2025 revenue decline, stock rises slightly

    Treace Medical Concepts reported Q4 2025 revenue of $62.5 million, a 9% decline year‑over‑year, and a loss per share of $0.16, missing expectations. Gross margin remained stable at 80.6%, while operating expenses rose slightly to $56.3 million. The company attributed the revenue decline to a shift in the product mix toward lower‑priced offerings. The stock gained 0.48% in premarket trading, and Treace plans several product launches in 2026 (including Lapiplasty Lightning and IntelliGuide PSI) to support growth. » Plus sur de.investing.com


  • Treace Medical adjusts strategy: product expansion and cost cuts to counter falling demand

    Treace Medical reports annual revenue of over $200 million but sees weaker demand for the Lapoplasty system. The company is expanding its portfolio for bunion treatments, introducing new lower-priced products, and stepping up surgeon training as well as AI-powered diagnostics with IntelliGuide. Financial measures include stable gross margins in the high-70% range and a 45% reduction in cash burn; further decisions are expected after the Q4 numbers. » Plus sur de.investing.com


  • Treace Medical raises Q3 revenue 11% to $50.2m but remains loss-making

    Treace Medical reported Q3 2025 revenue up 11% to $50.2m, above analysts’ estimate of $49.66m. The company recorded a net loss of $16.3m, or $0.26 per share; gross margin fell to 79.1%. Adjusted EBITDA loss improved 49% to $2.6m. For 2025 Treace expects revenue of $211–213m and an adjusted EBITDA loss of $6.5–7.5m; management emphasizes a focus on profitability and market expansion. » Plus sur de.investing.com


  • Treace Medical Concepts beats Q2 forecasts and shares rise after hours

    Treace Medical Concepts Inc. reported a Q2 2025 loss per share of $0.28 versus $0.29 expected and revenue of $47.4 million, topping estimates. Net loss and adjusted EBITDA improved significantly; the stock rose 3.84% after hours. For 2025, the company guides to $224–$230 million in revenue and breakeven on adjusted EBITDA, supported by new product launches and market expansion. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, Treace Medical Concepts a réalisé un chiffre d'affaires de 42,6 M € et un bénéfice net de -11,09 M €
(EUR) septembre 2026
YoY
Chiffre d'affaires 42,6 M 0,44 %
Bénéfice brut 33,86 M 0,07 %
Bénéfice net -11,09 M 20,07 %
EBITDA -9,7 M 6,52 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
264,93 M €
Nombre d'actions
65,56 M
Plus haut/bas sur 52 semaines
4,95 € - 1,06 €
Dividendes Non
Bêta
1,56
Ratio P/E
-5,16
Ratio PEG
0,49
Ratio P/B
4,72
Ratio P/S
1,43

Profil de l'entreprise

Treace Medical Concepts, Inc., une entreprise de dispositifs médicaux orthopédiques, se consacre à la conception, à la fabrication et à la commercialisation de dispositifs médicaux destinés aux chirurgiens du pied et de la cheville aux États-Unis. Elle propose la procédure Lapiplasty, qui permet aux chirurgiens podologues de traiter les trois dimensions de l'hallux valgus, offrant aux patients une amélioration esthétique et médicale. La société fournit également le système de précision Lapiplasty Mini-Incision. Par ailleurs, elle propose des produits destinés aux procédures chirurgicales annexes, notamment les ostéotomies d'Akin, les ostéotomies de Weil, la stabilisation intercunéiforme, les arthrodèses de l'articulation tarso-métatarsienne latérale et le prélèvement d'autogreffe osseuse, ainsi que pour l'arthrodèse MTP. Treace Medical Concepts, Inc. a été fondée en 2013 et son siège social se trouve à Ponte Vedra Beach, en Floride.

Nom
Treace Medical Concepts
PDG
John T. Treace
Siège social Ponte Vedra, fl
États-Unis
Site web
Secteur
Consommation discrétionnaire
Industrie
Biens de consommation durables
Introduction en bourse
23/04/2021
Employés 450

Symboles boursiers

Bourse Symbole
NASDAQ
TMCI
🍪

Parqet  utilise des cookies. En savoir plus